KAISHA Pharma is embarking on a new chapter in its development of pharmaceutical glass primary packaging, with a strong focus on innovation, quality and international growth.

OCMI-OTG S.p.A. is proud to contribute to this ambitious project, supplying 19 of the 25 new ampoule production lines that will support KAISHA Pharma’s development.

The project is part of a much longer history for OCMI. For 104 years, the company has been developing and manufacturing machinery for the glass industry, with a particular focus on pharmaceutical primary packaging. Today, more than 3,000 OCMI references are active on the market, supporting customers across different applications and production environments.

KAISHA Pharma’s investment is also a clear example of the role that specialised machinery plays in the development of new pharmaceutical glass production capabilities. For OCMI, contributing to a project of this scale means bringing decades of industrial experience and technological expertise to a new generation of production lines.

Innovation has always gone hand in hand with industrial experience at OCMI. This combination has allowed the company to work alongside major players in the glass and pharmaceutical industries, supporting projects that require reliable and advanced production technology. The KAISHA Pharma project is a further example of this approach, with OCMI supplying the majority of the new ampoule production lines and contributing its experience to the development of a new chapter in pharmaceutical glass.